On November 4, 2021 Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, reported that new preclinical data on its small-molecule MALT1 inhibitors will be presented during a poster session at the American Society of Hematology (ASH) (Free ASH Whitepaper) 63rd Annual Meeting taking place virtually and in Atlanta, Georgia, December 11-14, 2021 (Press release, Schrodinger, NOV 4, 2021, View Source [SID1234594533]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Inhibiting MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is considered a potentially promising therapeutic approach for the treatment of certain subtypes of non-Hodgkin B-cell lymphomas and for chronic lymphocytic leukemia (CLL). Schrödinger has identified a number of small-molecule MALT1 inhibitors, the most advanced of which is expected to enter the clinic next year.
Details of the poster presentation are as follows:
Title: Characterization of Potent Paracaspase MALT1 Inhibitors for Hematological Malignancies
Abstract number: 1187
Date & time: Saturday, December 11, 5:30 p.m. – 7:30 p.m. EST
Location: Georgia World Congress Center, Hall B5